How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

158 results for

Pancoast Tumor

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer

Posted: November 26, 2015 Last Update Posted: June 28, 2016 Last Verified: May 2016 Additional relevant MeSH terms: Layout table for MeSH terms Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Paclitaxel Etoposide Vinorelbine Cisplatin Carboplatin Etoposide phosphate Pemetrexed Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin (...) Posted : June 28, 2016 Sponsor: Eli Lilly and Company Information provided by (Responsible Party): Eli Lilly and Company Study Details Study Description Go to Brief Summary: This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology. Condition or disease Intervention/treatment Phase Non Small Cell Lung Cancer Drug: Pemetrexed Drug: Cisplatin Drug: Etoposide Drug: Vinorelbine Drug: Paclitaxel Drug

2008 Clinical Trials

122. CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer

, 2008 Last Update Posted: June 27, 2017 Last Verified: June 2017 Keywords provided by Accuray Incorporated: lung cancer lung tumor non-small cell lung cancer NSCLC CyberKnife radiosurgery lung surgery Additional relevant MeSH terms: Layout table for MeSH terms Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms (...) radiation therapy in the same field as the planned treatment area in the past. The patient has completed chemotherapy within less than 30 days of treatment. T2: Tumor size > 5 cm, T3 tumors (except T3 by virtue of chest wall invasion and ≤ 5 cm), T4 tumors. Presence of N1, N2 or N3 disease per previously described criteria would be excluded. Pancoast tumors would be excluded. Current distant metastatic disease (M1) (preferably biopsy proven). The patient is a female with child-bearing potential who

2008 Clinical Trials

123. Surgery, Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer

, primary bronchogenic non-small cell lung cancer meeting the following subtypes: Adenocarcinoma (no bronchioalveolar cell histology) Squamous cell carcinoma Large cell carcinoma Meeting the following staging criteria: Stage IIB (T2, N1, M0, or T3, N0, M0) Stage IIIA (T1-3, N2, M0 or T3, N1, M0) Stage IIIB (Any T, N3, M0 or T4, Any N, M0) No more than 1 parenchymal lesion in the same lung or in both lungs No tumor involving the superior sulcus (e.g., Pancoast tumor) Patients must undergo evaluation (...) ) SGOT and SGPT ≤ 3 times ULN Creatinine clearance > 50 mL/min No prior malignancy except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, ductal or lobular carcinoma in situ of the breast, or any other cancer from which the patient has been disease-free for 5 years Not pregnant or nursing Negative pregnancy test Fertile patients must use effective protection No significant hearing loss or patient unwilling to accept potential for further hearing loss

2007 Clinical Trials

124. Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer

. No positive supraclavicular or scalene lymph nodes extending up into the cervical region. No superior sulcus (pancoast tumors). No malignant pleural effusions. The only exception is a patient with a pleural effusion visible only on CT scan (and not visible on CXR) OR deemed too small to tap. No clinically significant or malignant pericardial effusions. No CNS metastases. No unintended weight loss (> 5% body weight) in the preceding 90 days prior to registration for initial therapy. No treatment with any (...) ClinicalTrials.gov Identifier: Other Study ID Numbers: HOG LUN06-107 First Posted: December 29, 2006 Results First Posted: July 25, 2016 Last Update Posted: July 25, 2016 Last Verified: May 2016 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Yes Additional relevant MeSH terms: Layout table for MeSH terms Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic

2006 Clinical Trials

125. Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy

have been amenorrheic at least for 12 months to be considered of non childbearing potential) Exclusion criteria: Presence of a Pancoast tumor Involvement of N2/N3 lymph nodes Distant metastases The following histological tumor types are excluded Pure bronchioloalveolar carcinoma Mixed cell carcinoma with small cell fractions Large Cell Carcinoma with areas of small cell carcinoma Pregnancy or lactation period Other co-existing malignancies or malignancies diagnosed within the last 5 years (...) drug administration should only be administered to patients with full recovery after surgery and is to begin on d28 to d42 postoperatively The following histological tumor types are eligible: Squamous Cell Carcinoma Adenocarcinoma (including adenocarcinomas with bronchioloalveolar differentiation) Large Cell Carcinoma (excluding tumors with slight areas of small cell carcinoma) Mixed Cell Carcinoma without small cell fraction Provision of informed consent according to local regulatory requirements

2006 Clinical Trials

126. Molecular Profiling in Lung Cancer Patients

or radiation therapy for NSCLC (prior resection of lung is allowed provided at least 5 years have elapsed between prior surgery and enrolment) Exclusion Criteria: bronchoalveolar carcinoma or stage IIIA tumor involving the superior sulcus (Pancoast tumors) pregnant or breast feeding patients patients who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry patients with history or presence of other malignancy (...) to Brief Summary: The main purpose of this study of pemetrexed combined with cisplatin used as neoadjuvant chemotherapy (2 or 3 cycles) in participants with operable non-small cell lung cancer (NSCLC) is to look at various genes present in participants' blood and tumor tissue to see if there is any link between the levels or changes in the genes and how participants with lung cancer respond to pemetrexed and cisplatin treatment. Condition or disease Intervention/treatment Phase Non-Small Cell Lung

2005 Clinical Trials

127. Total spondylectomy for en bloc resection of lung cancer invading the chest wall and thoracic spine. Case report. (Abstract)

Total spondylectomy for en bloc resection of lung cancer invading the chest wall and thoracic spine. Case report. Lung cancers invading the chest wall and spinal column are often considered unresectable, and consequently there are few reports describing resection of invasive vertebral lesions. The authors developed a new anterior approach procedure for the en bloc resection of primary lung adenocarcinoma invading the thoracic spine and chest wall, in which the primary tumor does not need (...) and posterior spinal instrumentation. At 46 months after surgery, there is no evidence of local recurrence or distant metastasis, and the patient continues to improve. This new procedure allows for the en bloc resection of primary lung tumors and adherent vertebral invasion without separation of the lesion from the vertebra. Thus, surgical management by complete excision of Pancoast tumors can achieve longer-term survival rates without sequelae.

2004 Journal of Neurosurgery

128. Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Full Text available with Trip Pro

Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). This chapter of the guidelines addresses patients who have particular forms of non-small cell lung cancer that require special considerations. This includes patients with Pancoast tumors, T4N0,1M0 tumors, satellite nodules in the same lobe, synchronous and metachronous multiple primary lung cancers (MPLCs), solitary brain and adrenal metastases, and chest wall involvement.The nature (...) by a standardized method (see "Methodology for Lung Cancer Evidence Review and Guideline Development" chapter), and reviewed by all members of the lung cancer panel before approval by the Thoracic Oncology NetWork, Health and Science Policy Committee, and the Board of Regents of the American College of Chest Physicians.In patients with a Pancoast tumor, a multimodality approach seems to be optimal, involving chemoradiotherapy and surgical resection, provided appropriate staging has been conducted. Patients

2007 Chest

129. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. (Abstract)

patients), IIIB (10 patients), and IV (2 patients with isolated brain metastasis). Thirteen patients exhibited Pancoast tumors. Median time from completion of induction therapy to surgery was 53 days. Twenty-nine lobectomies and 11 pneumonectomies (7 right, 4 left) were performed. There were no postoperative deaths. Intercostal muscle flaps were used prophylactically in all but one pneumonectomy patient. Seven patients required perioperative transfusions. Median intensive care unit (ICU) time averaged (...) Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. Pulmonary resection after chemotherapy and concurrent full-dose radiotherapy (>59 Gy) has previously been associated with unacceptably high morbidity and mortality. Subsequently neoadjuvant therapy protocols have used reduced and potentially suboptimal radiotherapy doses of 45 Gy. We report a series of 40 patients with locally advanced non-small-cell lung cancer who

2004 Annals of Thoracic Surgery

130. Lung cancer with chest wall involvement: predictive factors of long-term survival after surgical resection. Full Text available with Trip Pro

resection was required in 20 patients. Resection was incomplete in three cases. In the PT group we had 15 patients: 11 were in stage IIB and 4 in stage IIIA. Histological type was adenocarcinoma in 10 cases, squamous cell carcinoma in 4 and adenosquamous carcinoma in 1. A univariate analysis performed in the CW group showed that survival was significantly affected by nodal status, stage, extension of chest wall invasion, type of lung resection and residual disease. In a multivariate analysis we found (...) with that of a group of patients affected by a Pancoast tumour and surgical treated in the same period.We reviewed records of 83 consecutive patients with NSCLC in stage T3 (owing to direct extension to chest wall), who underwent surgical resection in our Thoracic Surgery Unit between January 1994 and December 2003. Patients were classified in two groups: pancoast tumours (PT) or chest wall extending tumours (CW): survival and prognostic factors of each category were analyzed.In the CW group we had 68 patients: 45

2006 Lung Cancer

131. S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer

Posted: January 27, 2003 Last Update Posted: January 31, 2013 Last Verified: January 2013 Keywords provided by Southwest Oncology Group: stage I non-small cell lung cancer stage II non-small cell lung cancer stage IIIA non-small cell lung cancer Additional relevant MeSH terms: Layout table for MeSH terms Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial (...) tumor cells. It is not yet known if surgery plus combination chemotherapy is more effective than surgery alone for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of surgery with or without combination chemotherapy in treating patients who have non-small cell lung cancer. Condition or disease Intervention/treatment Phase Lung Cancer Drug: carboplatin Drug: paclitaxel Procedure: conventional surgery Phase 3 Detailed Description: OBJECTIVES: Compare

1999 Clinical Trials

132. S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer

: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically or cytologically confirmed, newly diagnosed, advanced primary non-small cell lung cancer (NSCLC) (adenocarcinoma, large cell carcinoma, squamous cell carcinoma, or unspecified), designated as 1 of the following stages: Selected stage IIIB (excluding Pancoast tumors) T4 lesion due to malignant pleural effusion OR Multiple lesions in a single lobe (...) by Southwest Oncology Group: recurrent non-small cell lung cancer squamous cell lung cancer large cell lung cancer stage IIIB non-small cell lung cancer stage IV non-small cell lung cancer adenocarcinoma of the lung Additional relevant MeSH terms: Layout table for MeSH terms Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Docetaxel Vinorelbine

2001 Clinical Trials

133. Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

of the superior sulcus, chest wall, or mediastinum Must have at least 1 of the following: Locally advanced Pancoast tumors with no documented mediastinal or supraclavicular nodal involvement (T3-T4, N0-1) Resectable chest wall disease (T3, N0-1) Marginally resectable T4, N0-1, or NX central NSCLC N2 patients who are potentially resectable after induction chemoradiotherapy No evidence of extrathoracic spread to liver, adrenals, brain, or bone No evidence of supraclavicular nodes, malignant pleural (...) during surgery and may kill any remaining tumor cells following surgery. PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel and carboplatin with radiation therapy and surgery in treating patients who have newly diagnosed locally advanced non-small cell lung cancer. Condition or disease Intervention/treatment Phase Lung Cancer Drug: carboplatin Drug: paclitaxel Procedure: conventional surgery Radiation: radiation therapy Phase 2 Detailed Description: OBJECTIVES: Determine

2002 Clinical Trials

134. S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

: October 2012 Keywords provided by Southwest Oncology Group: recurrent non-small cell lung cancer squamous cell lung cancer large cell lung cancer stage IIIB non-small cell lung cancer stage IV non-small cell lung cancer adenocarcinoma of the lung Additional relevant MeSH terms: Layout table for MeSH terms Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial (...) carcinoma, squamous cell carcinoma, or unspecified) or recurrent non-small cell lung cancer after previous surgery and/or radiotherapy Stage IIIB: T4 lesion due to malignant pleural effusion, OR multiple lesions in a single lobe containing a T3 or T4 primary, OR lesions in multiple lobes of the ipsilateral lung for which one such lesion is T3 or T4 Any N M0 Stage IV: Any T, Any N, M1 Measurable or evaluable disease Measurable or evaluable disease must be outside of the prior radiotherapy port or prior

1999 Clinical Trials

135. SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung Cancer

Oncology Group: squamous cell lung cancer large cell lung cancer stage IIIA non-small cell lung cancer stage IIIB non-small cell lung cancer adenocarcinoma of the lung adenosquamous cell lung cancer Additional relevant MeSH terms: Layout table for MeSH terms Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Etoposide Antineoplastic Agents (...) CHARACTERISTICS: Histologically or cytologically proven non-small cell lung cancer of any type Selected stage IIIA/B disease (T3-4, N0-1, M0) with superior sulcus involvement, including: Apical tumor without rib or vertebral body involvement, with Pancoast syndrome Superior sulcus tumor with involvement of the chest wall (T3) and usually ribs 1 and 2 by CT or MRI, with or without Pancoast syndrome Superior sulcus tumor with involvement of vertebral body or subclavian vessels (T4) by CT or MRI, with or without

1999 Clinical Trials

136. Lung cancer. Special treatment issues. (Abstract)

Lung cancer. Special treatment issues. This chapter of the Lung Cancer Guidelines addresses patients with particular forms of non-small cell lung cancer that require special considerations. This includes patients with Pancoast tumors, T4N0,1M0 tumors, satellite nodules in the same lobe, synchronous and metachronous multiple primary lung cancers (MPLC), and solitary metastases. For patients with a Pancoast tumor, a multimodality approach, involving chemoradiotherapy and surgical resection (...) be dictated by the primary tumor alone. On the other hand, it is difficult to know how best to treat patients with a focus of the same type of cancer in a different lobe. Although MPLC do occur, the survival results after resection for either a synchronous presentation or a metachronous presentation with an interval of < 4 years between tumors are variable and generally poor, suggesting that many of these patients may have had a pulmonary metastasis rather than a second primary lung cancer. A thorough

2003 Chest

137. Non-small cell lung carcinoma of the superior sulcus: Favourable outcomes of combined modality treatment in carefully selected patients. (Abstract)

Non-small cell lung carcinoma of the superior sulcus: Favourable outcomes of combined modality treatment in carefully selected patients. The combination of radiotherapy and concurrent chemotherapy followed by surgery (trimodality treatment) is currently regarded as optimal treatment for non-small cell lung cancer of the superior sulcus (SST) or Pancoast tumour. The possibility to administer intensive combined modality treatment is influenced by tumour stage, comorbidity and performance status (...) of these patients, and therefore a strict patient selection is necessary. This study focuses on patient selection and its results. We retrospectively evaluated choices of treatment and outcome of all patients with SST treated in the Netherlands Cancer Institute from 1994 to 2004. After identification of patients with SST in registration databases, the following characteristics were analyzed: symptoms, comorbidity, tumour stage, treatment characteristics, toxicity, local control, disease-free and overall

2007 Lung Cancer

138. Posterior cervicothoracic instrumentation in spine tumors. (Abstract)

of 52 years. A total of 32 cervicothoracic instrumentations were performed. We used the R. Roy-Camille thoracolumbar plate in 20 patients, the cervico-thoracic plate in 8, and the Agora rod system in 4. In all, 96 lateral mass screws were implanted from C4 to C6, 54 into C7, and 180 pedicle screws from T1 to T8. Nineteen patients had lung cancer with vertebral body invasion (Pancoast tumors), 11 had metastasis to the cervicothoracic junction, 1 had a chondrosarcoma, and 1 had myeloma. In a first (...) Posterior cervicothoracic instrumentation in spine tumors. We retrospectively review 32 patients who underwent posterior fixation for cervicothoracic junctional tumors. All patients possessed unstable or potential after surgery unstable spines as a result of either their tumors or the surgery performed. We examined cervicothoracic spine stability, maintenance of alignment, and associated complications.To review our experience with 3 different posterior osteosynthesis systems applied

2004 Spine

139. Radical excision in the management of thoracic and cervicothoracic tumors involving the spine: results in a series of 36 cases. (Abstract)

Radical excision in the management of thoracic and cervicothoracic tumors involving the spine: results in a series of 36 cases. A new surgical technique for en bloc resection of posterior mediastinum tumors invading the spine is described.To demonstrate that major soft tissue tumors of the thoracic apex (Pancoast Tobias syndrome) or posterior mediastinum tumors can be removed en bloc even though the vertebral body or the foramina are invaded.En bloc surgery of tumor is accepted today as being (...) the goal of carcinologic surgery with the best results for survival. Until now, no surgical technique has been described for radical excision of soft tissue tumors invading the thoracic spine adjacent to the ribs and lung. We reviewed our 8 years' experience of 36 such cases and report outcome and survival rates.The authors have joined their abilities and technique to enable complete en bloc extratumoral resections of lung tumors or posterior mediastinum tumors invading the adjacent soft tissue

2003 Spine

140. Pancoast's syndrome secondary to lung infection with cutaneous fistulisation caused by Staphylococcus aureus. Full Text available with Trip Pro

Pancoast's syndrome secondary to lung infection with cutaneous fistulisation caused by Staphylococcus aureus. Apical bronchial carcinoma is the most common cause of Pancoast's syndrome. Of the many other causes reported, infection is a rare one. A literature review is presented and a case of Pancoast's syndrome, secondary to apical lung pneumonia with bronchocutaneous fistulisation caused by Staphylococcus aureus infection, is reported. Clinical and radiological resolution was achieved after

2006 Journal of Clinical Pathology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>